Each filer's latest filing for 36315X101 since 12/18/2024, largest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Gilead Sciences, Inc.
13D/A
|
29.9% |
1/10/2025
Event 1/7/2025
|
|
| Gilead Sciences, Inc. | 29.9% | ||
| Gilead Therapeutics A1 Unlimited Company | 29.9% | ||
|
EcoR1 Capital, LLC
13D/A
|
13.2% |
7/28/2025
Event 7/24/2025
|
|
| EcoR1 Capital, LLC | 13.2% | ||
| Oleg Nodelman | 13.2% | ||
| EcoR1 Capital Fund Qualified, L.P. | 12.4% | ||
| EcoR1 Capital Fund, L.P. | 0.8% | ||
|
Tang Capital Management LLC
13G
|
8.4% |
10/29/2025
Event 10/27/2025
|
|
| Tang Capital Management, LLC | 8.4% | ||
| Kevin Tang | 8.4% | ||
| Tang Capital Partners, LP | 5.0% | ||
| Tang Capital Partners International, LP | 3.4% | ||
| Tang Capital Partners III, Inc | 0% | ||
| Tang Capital Partners IV, Inc | 0% | ||
|
Madison Avenue Partners, LP
13G
|
5.5% |
6/23/2026
Event 6/15/2026
|
|
| Madison Avenue International LP | 5.5% | ||
| Madison Avenue Partners, LP | 5.5% | ||
| EMAI Management, LLC | 5.5% | ||
| Madison Avenue GP, LLC | 5.5% | ||
| Caraway Jackson Investments LLC | 5.5% | ||
| Eli Samaha | 5.5% |
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 95 | 33.6 M | $1.00B |
| 2026 Q2 | 78 | 32.1 M | $960M |
| 2026 Q1 | 90 | 31.3 M | $938M |
| 2025 Q4 | 91 | 31.4 M | $1.03B |
| 2025 Q3 | 94 | 31.5 M | $1.09B |
| 2025 Q2 | 89 | 31.7 M | $887M |
| 2025 Q1 | 87 | 31.2 M | $783M |
| 2024 Q4 | 85 | 31.1 M | $857M |
| 2024 Q3 | 81 | 13.7 M | $393M |
| 2024 Q2 | 86 | 19.9 M | $494M |
| 2024 Q1 | 86 | 20.5 M | $660M |
| 2023 Q4 | 90 | 19.8 M | $804M |
| 2023 Q3 | 74 | 19.2 M | $662M |
| 2023 Q2 | 79 | 19.7 M | $801M |
| 2023 Q1 | 79 | 18.2 M | $704M |
| 2022 Q4 | 77 | 13.2 M | $585M |
| 2022 Q3 | 85 | 12.9 M | $551M |
| 2022 Q2 | 87 | 12.9 M | $720M |
| 2022 Q1 | 96 | 12.8 M | $796M |
| 2021 Q4 | 85 | 10.8 M | $600M |
| 2021 Q3 | 84 | 8.55 M | $450M |
| 2021 Q2 | 111 | 7.51 M | $517M |
| 2021 Q1 | 135 | 6.57 M | $506M |
| 2020 Q4 | 117 | 4.56 M | $452M |
| 2020 Q3 | 121 | 7.42 M | $1.05B |
| 2020 Q2 | 143 | 7.63 M | $1.50B |
| 2020 Q1 | 144 | 7.66 M | $1.50B |
| 2019 Q4 | 139 | 7.56 M | $1.56B |
| 2019 Q3 | 113 | 8.46 M | $1.29B |
| 2019 Q2 | 104 | 8.62 M | $1.11B |
| 2019 Q1 | 97 | 8.43 M | $993M |
| 2018 Q4 | 89 | 8.13 M | $746M |
| 2018 Q3 | 97 | 9.43 M | $1.06B |
| 2018 Q2 | 80 | 7.62 M | $702M |
| 2018 Q1 | 82 | 8.97 M | $894M |
| 2017 Q4 | 78 | 9.94 M | $932M |
| 2017 Q3 | 70 | 10.1 M | $1.03B |
| 2017 Q2 | 78 | 12.1 M | $922M |
| 2017 Q1 | 66 | 10.1 M | $868M |
| 2016 Q4 | 52 | 9.99 M | $642M |
| 2016 Q3 | 47 | 9.71 M | $628M |
| 2016 Q2 | 38 | 9.79 M | $543M |
| 2016 Q1 | 32 | 8.77 M | $367M |
| 2015 Q4 | 44 | 8.24 M | $518M |
| 2015 Q3 | 38 | 9.05 M | $368M |
| 2015 Q2 | 41 | 8.81 M | $453M |